FDA Approves Lantheus Alzheimer Imaging Agent
The US Food and Drug Administration approved Lantheus Holdings and its new radioactive agent to help assess patients for Alzheimer disease. The product highlights tau protein deposits in brain scans.
X24 PerspectiveRelated Assets:
X24 Perspective